The assessment of beta amyloid, tau protein and cystatin C in the cerebrospinal fluid: laboratory markers of neurodegenerative diseases
Language English Country Italy Media print-electronic
Document type Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Alzheimer Disease cerebrospinal fluid diagnosis physiopathology MeSH
- Amyloid beta-Peptides analysis cerebrospinal fluid MeSH
- Biomarkers analysis cerebrospinal fluid MeSH
- Cystatin C analysis cerebrospinal fluid MeSH
- Nerve Degeneration cerebrospinal fluid diagnosis physiopathology MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Peptide Fragments analysis cerebrospinal fluid MeSH
- Predictive Value of Tests MeSH
- tau Proteins analysis cerebrospinal fluid MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Up-Regulation physiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Controlled Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- amyloid beta-protein (1-42) MeSH Browser
- Amyloid beta-Peptides MeSH
- Biomarkers MeSH
- Cystatin C MeSH
- Peptide Fragments MeSH
- tau Proteins MeSH
To assess the role of tau protein, beta-amyloid(1-42) and cystatin C in the diagnostics of Alzheimer dementia (AD) and other neurodegenerative diseases (ND) by comparing to the control groups (CG). The levels of tau protein, beta-amyloid(1-42) and cystatin C were assessed in the set of 69 patients (AD + ND, 33 males, 36 females, aged 22-90, mean 60.5 + 16.1 years), and in a control group of 69 subjects without the affection of the central nervous system (CGAD + CGND, 33 males, 36 females, aged 20-91, mean 60.5 + 16.0 years). Statistically significant increased tau protein levels (P = 0.0001) and index tau/beta-amyloid(1-42) levels (P = 0.0002) were shown in the group of AD patients, compared to the group of ND patients. One-way ANOVA analysis with Bonferonni post hoc test did not show any significant differences of the cystatin C values between any of the compared groups. ROC analysis showed at least one tie between the positive actual state group (AD) and the negative actual state group (ND) by CSF cystatin C and at least one tie between the positive actual state group and the negative actual state group by CSF tau protein. Our study confirmed previously reported results only in part. While tau protein seems to be quite a reliable marker of AD, the role of beta-amyloid(1-42) and cystatin C in AD diagnosis remains at least questionable.
See more in PubMed
Eur J Immunol. 2001 Jun;31(6):1813-24 PubMed
Stroke. 1996 Aug;27(8):1417-9 PubMed
Brain Pathol. 2006 Jan;16(1):60-70 PubMed
Neurology. 2005 Feb 22;64(4):755-7 PubMed
Acta Neurol Scand. 2000 Apr;101(4):279-82 PubMed
J Neurol Sci. 1996 Sep 1;140(1-2):101-8 PubMed
Neurosci Lett. 2001 Nov 23;315(1-2):17-20 PubMed
Neurology. 1997 Mar;48(3):632-5 PubMed
Nat Genet. 2007 Dec;39(12):1437-9 PubMed
Mol Chem Neuropathol. 1995 Dec;26(3):231-45 PubMed
J Cell Mol Med. 2008 Aug;12(4):1094-117 PubMed
Ann Neurol. 1995 Oct;38(4):643-8 PubMed
Clin Chem Lab Med. 2001 Sep;39(9):850-7 PubMed
Arch Neurol. 2001 Mar;58(3):373-9 PubMed
Neurol Med Chir (Tokyo). 2001 Oct;41(10):471-7; discussion 477-8 PubMed
Neurology. 2001 Jul 24;57(2):337-9 PubMed
J Neuroendocrinol. 1997 Apr;9(4):247-53 PubMed
Brain Res. 1995 Sep 11;691(1-2):1-8 PubMed
Brain Res Mol Brain Res. 1996 Apr;37(1-2):273-82 PubMed
Neurology. 1999 May 12;52(8):1555-62 PubMed
